Arbutus Biopharma Co. (NASDAQ:ABUS) is Two Seas Capital LP's 10th Largest Position

Two Seas Capital LP grew its holdings in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 4.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,740,956 shares of the biopharmaceutical company's stock after purchasing an additional 353,568 shares during the period. Arbutus Biopharma makes up approximately 2.2% of Two Seas Capital LP's investment portfolio, making the stock its 10th largest holding. Two Seas Capital LP owned 4.61% of Arbutus Biopharma worth $28,583,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ABUS. E Fund Management Co. Ltd. acquired a new stake in shares of Arbutus Biopharma in the fourth quarter valued at $34,000. Xponance Inc. bought a new stake in Arbutus Biopharma in the fourth quarter worth about $34,000. Raymond James Financial Inc. acquired a new stake in Arbutus Biopharma in the 4th quarter valued at about $34,000. Cibc World Markets Corp bought a new position in shares of Arbutus Biopharma during the 4th quarter valued at about $45,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Arbutus Biopharma in the 4th quarter worth approximately $55,000. 43.79% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ABUS has been the subject of several recent research reports. Chardan Capital reissued a "buy" rating and set a $5.00 target price on shares of Arbutus Biopharma in a research note on Friday, March 28th. Wall Street Zen upgraded Arbutus Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday, March 29th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Arbutus Biopharma has an average rating of "Moderate Buy" and an average target price of $5.50.

Arbutus Biopharma Stock Performance

Shares of ABUS remained flat at $3.22 during midday trading on Monday. 532,457 shares of the company's stock traded hands, compared to its average volume of 996,433. The stock's fifty day moving average price is $3.27 and its 200-day moving average price is $3.34. The company has a market capitalization of $616.72 million, a price-to-earnings ratio of -7.49 and a beta of 1.50. Arbutus Biopharma Co. has a one year low of $2.71 and a one year high of $4.73.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The biopharmaceutical company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.04). Arbutus Biopharma had a negative return on equity of 68.18% and a negative net margin of 1,137.65%. The firm had revenue of $1.76 million during the quarter, compared to analyst estimates of $2.54 million. On average, equities analysts anticipate that Arbutus Biopharma Co. will post -0.39 earnings per share for the current year.

Arbutus Biopharma Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.